ArticleOpen forum infectious diseases2026
Integrating Precision Sepsis Risk Stratification Into Systems-Based Antimicrobial Stewardship.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early broad-spectrum antimicrobial administration in sepsis is strongly associated with improved survival. However, widespread implementation of time-based antibiotic mandates has substantially increased antimicrobial utilization, contributing to escalating global antimicrobial resistance. This creates a fundamental tension in sepsis care: Aggressive empiric therapy optimizes short-term outcomes for individual patients but threatens long-term antimicrobial effectiveness at a population level. This perspective frames the "sepsis-antimicrobial stewardship tension" as a systems-level problem driven by diagnostic uncertainty, organizational incentives, and guideline implementation. We review emerging evidence demonstrating heterogeneity in the benefit of early antibiotics and highlight how rigid quality metrics, such as the US Centers for Medicare & Medicaid Services SEP-1 measure, may exacerbate unnecessary antimicrobial use. Finally, we discuss how advances in artificial intelligence, machine learning, and host-response diagnostics can enable precision risk-guided antimicrobial timing. Integrating these tools into clinical workflows via health systems engineering offers a path toward addressing antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.